How do I subscribe to ongoing alerts?

Subscribe to /feed/company/national-medical-research-center-for-children-s-health-russian-federation.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

National Medical Research Center for Children's Health, Russian Federation — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

National Medical Research Center for Children's Health, Russian Federation pipeline: 6 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Dupilumab therapy	Dupilumab therapy	marketed	Monoclonal Antibody	IL-4Rα	Immunology
cream 0.1% methylprednisolone aceponate	cream 0.1% methylprednisolone aceponate	marketed
Mycophenolate mofetil therapy	Mycophenolate mofetil therapy	marketed
Ustekinumab Injection	Ustekinumab Injection	marketed	IL-12/IL-23 inhibitor (monoclonal antibody)	IL-12/IL-23 p40 subunit	Immunology
Methotrexate therapy	Methotrexate therapy	marketed	Folate antagonist / Antimetabolite	Dihydrofolate reductase (DHFR)	Oncology, Immunology, Rheumatology
Cyclosporine therapy	Cyclosporine therapy	marketed	Calcineurin inhibitor	Calcineurin (protein phosphatase 2B)	Immunology

Therapeutic area mix

Immunology · 3
Oncology, Immunology, Rheumatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Al-Azhar University · 1 shared drug class
Albert Einstein Healthcare Network · 1 shared drug class
Allergan · 1 shared drug class
Andrew B Adams · 1 shared drug class
Armando Torres Ramírez · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Astellas Pharma China, Inc. · 1 shared drug class
AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for National Medical Research Center for Children's Health, Russian Federation:

Cite this brief

Drug Landscape (2026). National Medical Research Center for Children's Health, Russian Federation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/national-medical-research-center-for-children-s-health-russian-federation. Accessed 2026-05-17.